Suchergebnisse - "Arbetter, Douglas"

PubPharm (15)

1

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups : real-world XALOC-1 programme

enthalten in: The European respiratory journal | 2024

von Jackson, D. | Pelaia, G. | Emmanuel, B. | +16

2

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19 : 15-Month Final Analysis of the TACKLE Trial

enthalten in: Infectious diseases and therapy | 2024

von Hobbs, F. | Montgomery, H. | Padilla, F. | +8

3

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

enthalten in: Infectious diseases and therapy | 2024

von Hobbs, F. | Montgomery, H. | Padilla, F. | +8

4

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

enthalten in: Infectious diseases and therapy | 2023

von Kijak, G. | Ahani, B. | Arbetter, D. | +13

5

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

enthalten in: Infectious diseases and therapy | 2023

von Kijak, G. | Ahani, B. | Arbetter, D. | +13

6

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

enthalten in: Infectious diseases and therapy | 2023

von Hobbs, F. | Montgomery, H. | Padilla, F. | +12

7

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

enthalten in: Infectious diseases and therapy | 2023

von Hobbs, F. | Montgomery, H. | Padilla, F. | +12

8

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE) : a phase 3, randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Respiratory medicine | 2022

von Montgomery, H. | Hobbs, F. | Padilla, F. | +118

CommentIn: Lancet Respir Med. 2022 Oct;10(10):930-931. - PMID 35688163

9

Competing risk analysis in a large cardiovascular clinical trial : An APEX substudy

enthalten in: Pharmaceutical statistics | 2017

von Arbetter, D. | Jain, P. | Yee, M. | +8

10

Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients : An APEX Trial Substudy

enthalten in: Journal of the American Heart Association | 2017

von Gibson, C. | Korjian, S. | Chi, G. | +11